Clinical development of recombinant human interleukin-11 to treat chemotherapy-induced thrombocytopenia

Current Opinion in Hematology

Volumn 3, Issue 3, 1996, Pages 209-215

  Kaye, James A ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; MESNA; RECOMBINANT INTERLEUKIN 11; THROMBOPOIETIN;

ARTHRALGIA; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER; CANCER CHEMOTHERAPY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; FATIGUE; HEADACHE; HUMAN; MEGAKARYOPOIESIS; MUCOSA INFLAMMATION; MYALGIA; NEUTROPENIA; NONHUMAN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; REVIEW; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA;

EID: 0030014438     PISSN: 10656251     EISSN: None     Source Type: Journal    
DOI: 10.1097/00062752-199603030-00008     Document Type: Review

References (58)

1. Paul SR, Bennett F, Calvetti JA, Kelleher K, Wood CR, O'Hara RM, Leary AC, Sibley B, Clark SC, Williams DA, Yang Y-C: Molecular cloning of a cDNA encoding interleukin-11, a stromal cell-derived lymphopoietic and hematopoietic cytokine. Proc Natl Acad Sd U S A 1990, 87:7512-7516.
2. Yin T, Taga T, Tsang M, Yasukawa K, Kishimoto T, Yang Y: Interleukin (IL)-6 signal transducer, gp130, is involved in IL-11 mediated signal transduction [abstract]. Blood 1992, 80:151a.
3. Yang Y-C, Yin T, McKinley D, Yang-Feng T, Paul S, Bennett F, Sibley B, Giannoti J, Clark SC: Molecular cloning and characterization of human interleukin-11. J Cell Biochem 1991, 15F:42.
4. McKinley D, Wu Q, Yang-Feng T, Yang Y-C: Genomic sequence and chromosomal location of human interleukin-11 (IL11). Genomics 1992, 13:814-819.
5. Czupryn MJ, McCoy JM, Scoble HA: Structure-function relationships in human interleukin-11 : identification of regions involved in activity by chemical modification and site-directed mutagenesis. J Biol Chem 1995, 270:978-985.
6. Hilton DJ, Hilton AA, Raicevic A, Rakar S, Harrison-Smith M, Gough NM, Begley CG, Metcalf D, Nicola NA, Willson TA: Cloning of a murine IL-11 receptor α-chain: requirement for gp130 for high affinity binding and signal transduction. EMBO J 1994, 13:4765-4775.
7. Chérel M, Sorel M, Lebeau B, Dubois S, Moreau J-F, Bataille R, Minvielle • S, Jacques Y: Molecular cloning of two isoforms of a receptor for the human hematopoietic cytokine interleukin-11. Blood 1995, 86:2534-2540. This French group used oligonucleotide primers that correspond to the conserved WSXWS motif found in the hematopoietic cytokine receptor family to identify cDNA that encodes the human interleukin-11 receptor. The human interleukin-11 receptor nucleotide sequence is highly homologous (82%) to that of the previously cloned murine interleukin-11 receptor. An interleukin-11 receptor isoform that lacks a cytoplasmic domain was identified, supporting the view that gp130 is the signal-transducing subunit in the receptor complex.
8. Kishimoto T, Akira S, Narazaki M, Taga T: Interleukin-6 family of • cytokines and gp130. Blood 1995, 86:1243-1254. This authoritative review of the cytokines that signal through gp130 identifies similarities and differences among interleukin-11 and other members of this family, which include interleukin-6, leukemia inhibitory factor, oncostatin M, and ciliary neurotrophic factor. Mechanisms of signal transduction by activation of the Jak and STAT kinases and the nuclear transcription factor NF-IL6 are discussed.
9. Yin T, Yang Y-C: Protein tyrosine phosphorylation and activation of primary response genes by interleukin 11 in B9-TY1 cells. Cell Growth Differ 1993, 4:603-609.
10. Yin T, Yasukawa K, Taga T, Kishimoto T, Yang Y-C : Identification of a 130-kilodalton tyrosine-phosphorylated protein Induced by interleukin-11 as JAK2 tyrosine kinase, which associates with gp130 signal transducer. Exp Hematol 1994, 22:467-472.
11. Berger LC, Hawley TS, Lust JA, Goldman SJ, Hawley RG: Tyrosine phosphorylation of JAK-TYK kinases in malignant plasma cell lines growth-stimulated by interleukins 6 and 11. Biochem Biophys Res Commun 1994, 202:596-605.
12. Czupryn M, Bennett F, Dube J, Grant K, Scoble H, Sookdeo H, McCoy JM: Alanine-scannlng mutagenesis of human interleukin-11: identification of regions Important for biological activity. Ann N Y Acad Sci 1995, 762:152-164.
13. Musashi M, Yang Y-C, Paul SR, Clark SC, Sudo T, Ogawa M: Direct and synergistic effects of interleukin 11 on murine hemopoiesis in culture. Proc Natl Acad Sci U S A 1991, 88:765-769.
14. Tsuji K, Lyman SD, Sudo T, Clark SC, Ogawa M: Enhancement of murine hematopoiesis by synergistic interactions between Steel factor (ligand for c-kit), interleukin-11, and other early acting factors in culture. Blood 1992, 79:2855-2860.
15. 0 and entry into the cell cycle of primitive human hemopoietic progenitors. Proc Natl Acad Sci U S A 1992, 89:4013-4017.
16. - cells and synergizes with stem cell factor, interleukin-3, and granulocyte-macrophage colony-stimulating factor. Exp Hematol 1993, 21:1668-1672.
17. Tanaka R, Katayama N, Ohishi K, Mahmud N, Itoh R, Tanaka Y, Komada Y, Minami N, Sakurai M, Shirakawa S, Shiku H: Accelerated cell-cycling of hematopoietic progenitor cells by growth factors. Blood 1995, 86:73-79.
18. Hirayama F, Shih J-P, Awgulewitsch A, Warr GW, Clark SC, Ogawa M: Clonal proliferation of murine lymphohemopoietic progenitors in culture. Proc Natl Acad Sci U S A 1992, 89:5907-5911.
19. Neben S, Donaldson D, Sieff C, Mauch P, Bodine D, Ferrara J, Yetz-Aldape J, Turner K: Synergistic effects of interleukin-11 with other growth factors on the expansion of murine hematopoletic progenitors and maintenance of stem cells in liquid culture. Exp Hematol 1994, 22:353-359.
20. Burstein SA, Mei R-L, Henthom J, Friese P, Turner K: Leukemia inhibitory factor and interleukin-11 promote maturation of murine and human megakaryocytes in vitro. J Cell Physiol 1992, 153:305-312.
21. Kobayashi S, Teramura M, Sugawara I, Oshimi K, Mizoguchi H: Interleukin-11 acts as an autocrine growth factor for human megakaryoblastic cell lines. Blood 1993, 81:889-893.
22. Yonemura Y, Kawakita M, Masuda T, Fujimoto K, Kato K, Takatsuki K: Synergistic effects of interleukin 3 and interleukin 11 on murine megakaryopoiesis in serum-free culture. Exp Hematol 1992, 20:1011-1016.
23. Teramura M, Kobayashi S, Hoshino S, Oshimi K, Mizoguchi H: Interleukin-11 enhances human megakaryocytopoiesis in vitro. Blood 1992, 79:327-331.
24. Banu N, Wang J, Deng B, Groopman JE, Avraham H: Modulation of megakaryocytopoiesis by thrombopoietin: the C-Mpl ligand. Blood 1995, 86:1331-1338.
25. Neben TY, Loebelenz J, Hayes L, McCarthy K, Stoudemire J, Schaub R, Goldman SJ: Recombinant human Interleukin-11 stimulates megakaryocytopoiesis and increases peripheral platelets in normal and splenectomized mice. Blood 1993, 81:901-908.
26. Yonemura Y, Kawakita M, Masuda T, Fujimoto K, Takatsuki K: Effect of recombinant human interleukin-11 on rat megakaryopoiesis and thrombopoiesis in vivo: comparative study with interleukin-6. Br J Haematol 1993, 84:16-23.
27. Leonard JP, Quinto CM, Kozitza MK, Neben TY, Goldman SJ: Recombinant human interleukin-11 stimulates multilineage hematopoietic recovery in mice after a myelosuppressive regimen of sublethal irradiation and carboplatln. Blood 1994, 83:1499-1506.
28. Leonard JP, Neben TY, Kozitza MK, Quinto CM, Goldman SJ: Constant subcutaneous Infusion of rhIL-11 in mice: efficient delivery enhances biological activity. Exp Hematol 1996, 24:270-276.
29. Goldman SJ: Preclinical biology of interleukin 11: a multifunctional •• hematopoietic cytokine with potent thrombopoietic activity. Stem Cells 1995, 13:462-471. An extensive review of the hematopoietic and thrombopoietic activities of interleukin-11 in normal and myelosuppressed animals, highlighting the stimulatory effects of interleukin-11 on hematopoietic progenitor cells, including megakaryocyte progenitors, and on megakaryocytes themselves. Increases in platelet production have been observed in multiple animal modela and in some cases stimulatory effects on leukocyte and erythrocyte recovery have been seen as well.
30. TH rhIL-11 growth factor) increases plasma von Willebrand factor and fibrinogen concentrations in normal human subjects [abstract]. Blood 1994, 84:276a.
31. Novik Y, Dutcher JP, Oleksowicz L: Interleukin-3 and interleukin-11: absence of an effect on in vitro agonist-induced platelet aggregation and platelet GMP-40 expression [abstract]. Blood 1995, 86:701a.
32. Oleksowicz L, Mrowiec Z, Zuckerman D, Isaacs R, Dutcher J, Puszkin E: Platelet activation Induced by interleukin-6: evidence for a mechanism Involving arachidonic acid metabolism. Thromb Haemost 1994, 72:302-308.
33. Peng J, Friese P, George JN, Dale GL, Burstein SA: Alteration of platelet function in dogs mediated by interleukin-6. Blood 1994, 83:398-403.
34. Hammond WP, Kaplan A, Kaplan S, Kaushansky K: Thrombopoietin (TPO) activates platelets in vitro [abstract]. Blood 1994, 84:534a.
35. de Sauvage FJ, Hass PE, Spencer SD, Malloy BE, Gurney AL, Spencer SA, Darbonne WC, Henzel WJ, Wong SC, Kuang W-J, Oles KJ, Hultgren B, Solberg LA Jr, Goeddel DV, Eaton DL: Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-Mpl ligand. Nature 1994, 369:533-538.
36. Herceg-Harjacek L, Groopman JE, Grabarek J: Thrombopoietin induces fibrinogen-mediated platelet-endothelial cell interaction [abstract]. Blood 1995, 86:84a.
37. Ault KA, Mitchell J, Knowles C: Recombinant human thrombopoietin augments spontaneous and ADP Induced platelet activation both in vitro and in vivo [abstract]. Blood 1995, 86:367a.
38. Ault KA, Rinder HM, Mitchell J, Carmody MB, Vary CPH, Hillman RS: The significance of platelets with increased RNA content (reticulated platelets): a measure of the rate of thrombopoiesis. Am J Clin Pathol 1992, 98:637-646.
39. Ault KA, Knowles C: In vivo biotinylation demonstrates that reticulated platelets are the youngest platelets in circulation. Exp Hematol 1995, 23:966-1001.
40. Du XX, Neben T, Goldman S, Williams DA: Effects of recombinant human interleukin-11 on hematopoietic reconstitution in transplant mice: acceleration of recovery of peripheral blood neutrophils and platelets. Blood 1993, 81:27-34.
41. Maze R, Moritz T, Williams DA: Increased survival and multilineage hematopoietic protection from delayed and severe myelosuppressive effects of a nitrosourea with recombinant interleukin-11. Cancer Res 1994, 54:4947-4951.
42. de Haan G, Dontje B, Engel C, Loeffler M, Nijhof W: In vivo effects of interleukin-11 and stem cell factor in combination with erythropoietin in the regulation of erythropoiesis. Br J Haematol 1995, 90:783-790.
43. Quesniaux VFJ, Clark SC, Turner K, Fagg B: Interleukin-11 stimulates multiple phases of erythropoiesis in vitro. Blood 1992, 80:1218-1223.
44. Paul SR, Hayes LL, Palmer R, Moms GE, Neben TY, Loebelenz J, Pedneault G, Brooks J, Blue I, Moore MAS, Muench M, Turner KJ, Schaub R, Goldman SJ, Wood CR: Interleukin-11 expression in donor bone marrow cells Imrpoves hematological reconstitution in lethally irradiated recipient mice. Exp Hematol 1994, 22:295-301.
45. Hawley RG, Fong AZC, Ngan BY, de Lanux VM, Clark SC, Hawley TS: Progenitor cell hyperplasia with rare development of myeloid leukemia in interleukin-11 bone marrow chimeras. J Exp Med 1993, 178:1175-1188.
46. TM rhIL-11 growth factor) in women with breast cancer receiving chemotherapy. Blood 1996, In press. In the phase I study of recombinant human interleukin-11 in patients with breast cancer, all subjects had increases in platelet counts after treatment with recombinant human interleukin-11. In addition, after moderately high-dose chemotherapy (cyclophosphamide and doxorubicin), patients receiving recombinant human interleukin-11 at doses of 25 to 75 μg/kg had higher nadirs than patients treated with 10 μg/kg. Treatment was well tolerated, with anemia being the most common side effect. Other studies have shown that this anemia is due to an increase in plasma volume, not a decrease in erythrocyte mass. (See Ault et al. [Blood 1994, 84:276a].)
47. TM rhIL-11 growth factor) in women with breast cancer receiving chemotherapy. Blood 1996, In press. In the phase I study of recombinant human interleukin-11 in patients with breast cancer, all subjects had increases in platelet counts after treatment with recombinant human interleukin-11. In addition, after moderately high-dose chemotherapy (cyclophosphamide and doxorubicin), patients receiving recombinant human interleukin-11 at doses of 25 to 75 μg/kg had higher nadirs than patients treated with 10 μg/kg. Treatment was well tolerated, with anemia being the most common side effect. Other studies have shown that this anemia is due to an increase in plasma volume, not a decrease in erythrocyte mass. (See Ault et al. [Blood 1994, 84:276a].)
48. Demetri GD, Hayes DF, Merica EA, Cap B, Sparano J: Concurrent IL-6 + G-CSF to support dose-Intensified cyclophosphamide/doxorubicin (CD): possible acceleration of hematologic recovery from chemotherapy-induced thrombocytopenia [abstract]. Blood 1994 B4:29a.
49. Kaushansky K, Lok S, Holly RD, Broudy VC, Lin N, Bailey MC, Forstrom JW, Buddle MM, Oort PJ, Hagen FS, Roth GJ, Papayannopoulou T, Foster DC: Promotion of megakaryocyte progenitor expansion and differentiation by the c-Mpl ligand thrombopoietin. Nature 1994, 369:568-571.
50. Tepler I, Elias L, Smith JW II, Hussein MA, Rosen G, Chang AY-C, Moore •• JO, Gordon MS, Kuca B, Beach K, Loewy J, Garnick MB, Kaye JA: A randomized trial of recombinant human interleukin eleven in cancer patients with a history of severe thrombocytopenia due to chemotherapy. Blood 1996, in press. The first randomized, placebo-controlled study that has shown a decrease in the number of patients with severe chemotherapy-induced thrombocytopenia who required platelet transfusions during their next chemotherapy cycle. The patients in this study had already been transfused platelets during a previous cycle because of severe chemotherapy-induced thrombocytopenia and they continued to receive the same chemotherapy (with no dose reductions) during the study. In patients receiving recombinant human interleukin-11, there also were trends toward fewer platelet transfusions and more rapid recovery to platelet counts of 50,000 and 100,000 cells/μL compared with patients in the placebo group.
51. Pisciotto PT, Benson K, Hume H, Glassman AB, Oberman H, Popovsky M, Hines D, Anderson K: Prophylactic versus therapeutic platelet transfusion practices in hematology and/or oncology patients. Transfusion 1995, 35:498-502.
52. TM rhIL-11 growth factor) increases plasma volume and decreases urine sodium excretion in normal human subjects [abstract]. Blood 1994, 84:276a.
53. Sonis S, Muska A, O'Brien J, VanVugt A, Langer-Safer P, Keith J: • Alteration in the frequency, severity and duration of chemotherapy-induced mucosltis in hamsters by interleukin-11. Oral Oncology 1995, 31B:261-266. A protective effect of interleukin-11 on the oral mucosa was observed in this model of fluorouracil-induced mucositis. This finding suggests that recombinant human interleukin-11 may have important clinical effects other than its ability to stimulate platelet production.
54. Potten CS: Interleukin-11 protects the clonogenic stem cells in murine • small-intestinal crypts from impairment of their reproductive capacity by radiation. Int J Cancer 1995, 62:356-361. In this animal model of radiation injury to the small bowel, interleukin-11 was shown to have direct protective effects on the clonogenic cells in the small intestinal crypts. Protection of these cells is one of several mechanisms through which interleukin-11 can ameliorate mucosal injury in a variety of animal models. (Also see Peterson et al. [Blood 1995, B6:311a] and Trepicchio et al. [Blood 1995, 86:924a].)
55. Potten CS: Interleukin-11 protects the clonogenic stem cells in murine • small-intestinal crypts from impairment of their reproductive capacity by radiation. Int J Cancer 1995, 62:356-361. In this animal model of radiation injury to the small bowel, interleukin-11 was shown to have direct protective effects on the clonogenic cells in the small intestinal crypts. Protection of these cells is one of several mechanisms through which interleukin-11 can ameliorate mucosal injury in a variety of animal models. (Also see Peterson et al. [Blood 1995, B6:311a] and Trepicchio et al. [Blood 1995, 86:924a].)
56. Potten CS: Interleukin-11 protects the clonogenic stem cells in murine • small-intestinal crypts from impairment of their reproductive capacity by radiation. Int J Cancer 1995, 62:356-361. In this animal model of radiation injury to the small bowel, interleukin-11 was shown to have direct protective effects on the clonogenic cells in the small intestinal crypts. Protection of these cells is one of several mechanisms through which interleukin-11 can ameliorate mucosal injury in a variety of animal models. (Also see Peterson et al. [Blood 1995, B6:311a] and Trepicchio et al. [Blood 1995, 86:924a].)
57. Peterson RL, Trepicchio WL, Bozza MM, Wang L, Domer AJ: G1 growth arrest and reduced proliferation of intestinal epithelial cells Induced by rhIL-11 may mediate protection against mucositis [abstract]. Blood 1995, 86:311a.
58. Trepicchio WL, Bozza M, Dorner AJ: Recombinant human interleukin-11 attenuates the inflammatory response through downregulation of prolnflammatory cytokine production and nitric oxide release [abstract]. Blood 1995, 86:424a.